Cresco Labs Stock Price, News & Analysis

Cresco Labs (CSE:CL, OTCQX:CRLBF) has announced the opening of its second Sunnyside dispensary in Pensacola, Florida, expanding its retail presence in the Florida Panhandle. This new location is the Company’s 54th nationwide. Despite challenges posed by Hurricane Ian, which affected store operations, Cresco has reopened its facilities and continues to serve Florida patients with medical cannabis. The Company is also engaged in community support initiatives, including food and water drives, to aid recovery efforts.

Cresco Labs announces its expansion into Florida, marking the launch of its flagship brand, Cresco, in its ninth market. The introduction includes a selection of Live Resin products available exclusively at Sunnyside dispensaries. The brand, known as the top-selling vape and concentrate brand in the U.S., aims to enhance product diversity for Florida patients. Cresco's Liquid Live Resin utilizes a patented extraction process that captures the strain's full-spectrum effects, making it a unique offering in the market.

Cresco Labs (CSE:CL, OTCQX:CRLBF) has successfully completed a sale-leaseback transaction for its Brookville, PA property, raising $45 million in non-dilutive funding. The property, which spans approximately 135,000 square feet, will continue to be operated by Cresco's subsidiary, Cresco Yeltrah, under a long-term lease with Aventine Property Group. CEO Charles Bachtell highlighted that this transaction unlocks valuable capital, enhancing their ability to invest in high-return opportunities, particularly in light of the forthcoming Columbia Care acquisition.

Cresco Labs (OTCQX: CRLBF) has expanded its Sunnyside retail brand in Florida with three new dispensaries located in Cape Coral, Tampa, and Panama City Beach. This addition increases Cresco's network to 19 stores in Florida and 53 nationwide. With nearly 750,000 qualified patients and over $2 billion in market revenue, Florida presents a significant growth opportunity. Further store openings are planned for late 2022 and early 2023, aiming to solidify Cresco's leading position in the cannabis market.

Cresco Labs reported a 4% year-over-year revenue growth of $218 million for Q2 2022, alongside an 11% increase in adjusted EBITDA to $51 million, reflecting resilience amid market challenges.

The company maintains its leadership as the no. 1 U.S. wholesaler of branded cannabis products, achieving a 53% adjusted gross margin.

It also noted progress in the ongoing acquisition of Columbia Care, anticipating a year-end closing. Cash on hand stood at $90 million as of June 30, 2022.

Cresco Labs (OTCQX: CRLBF), a leading U.S. wholesaler of cannabis products, has announced that Parkway Dispensary and Navāda Labs have received conditional adult-use dispensary licenses in Illinois. This follows the issuance of 185 new licenses aimed at promoting inclusivity in the cannabis industry. Cresco's SEED initiative has played a vital role in assisting social equity applicants throughout the process. Currently, Illinois has 110 dispensaries, and the new licenses will significantly increase access to cannabis products for consumers.

Cresco Labs (CSE:CL, OTCQX:CRLBF), a leading U.S. cannabis wholesaler, will announce its Q2 2022 financial results on August 17, 2022, before market opening. The company plans to hold a conference call at 8:30 AM EST to discuss the results and key business highlights. After the event, an archive of the webcast will be available for one year on the Cresco Labs investor relations website. Cresco Labs aims to normalize the cannabis industry while operating the largest social equity and educational initiative in the sector.

Cresco Labs (CSE:CL, OTCQX:CRLBF) held its annual shareholder meeting on July 15, 2022, where shareholders approved the election of 11 directors, including Charles Bachtell and Robert M. Sampson. Marcum LLP was reappointed as auditor. A significant resolution was passed regarding the company's Super Voting Shares, amending the investment agreement to facilitate a share repurchase for $800,001 after a future U.S. listing event. This decision prevents the issuance of new Super Voting Shares and mandates cancellation upon repurchase.

Columbia Care Inc. (CCHWF) has received final approval from the Supreme Court of British Columbia for its acquisition by Cresco Labs (CRLBF). This follows overwhelming shareholder support during a meeting on July 8, 2022. The CEO, Nicholas Vita, emphasized the milestone in achieving a leading position in the cannabis industry. The arrangement includes a divestiture process in key states, progressing well with strong demand from bidders. The divestitures are expected to align with the Arrangement's closing anticipated at the end of 2022.